Menu Search
Equities

Biontech SE

BNTX:NSQ

Biontech SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)112.17
  • Today's Change3.94 / 3.64%
  • Shares traded947.58k
  • 1 Year change+14.51%
  • Beta0.1977
Data delayed at least 15 minutes, as of Nov 22 2024 20:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform10
Hold5
Sell1
Strong Sell0

Share price forecast in EUR

The 19 analysts offering 12 month price targets for BioNTech SE - ADR have a median target of 135.12, with a high estimate of 169.89 and a low estimate of 97.41. The median estimate represents a 24.85% increase from the last price of 108.23.
High57.0%169.89
Med24.8%135.12
Low-10.0%97.41

Earnings history & estimates in EUR

On Nov 04, 2024, BioNTech SE - ADR reported 3rd quarter 2024 earnings of 0.81 per share. This result exceeded the -1.56 consensus loss of the 11 analysts covering the company and exceeded last year's 3rd quarter results by 20.90%.
The next earnings announcement is expected on Mar 25, 2025.
Average growth rate+13.55%
BioNTech SE - ADR reported annual 2023 earnings of 3.83 per share on Mar 20, 2024.
Average growth rate+21,951.82%
More ▼

Revenue history & estimates in EUR

BioNTech SE - ADR had 3rd quarter 2024 revenues of 1.24bn. This bettered the 587.81m consensus of the 11 analysts covering the company. This was 2.52% below the prior year's 3rd quarter results.
Average growth rate+203.42%
BioNTech SE - ADR had revenues for the full year 2023 of 3.82bn. This was 77.94% below the prior year's results.
Average growth rate+1,022.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.